E-LIB Suche - Ergebnisse für: Bodet Milin, C.

1

Promising clinical performance of pretargeted immuno-PET wi..:

Touchefeu, Y. ; Bailly, C. ; Frampas, E....
European Journal of Nuclear Medicine and Molecular Imaging. 48 (2020) 3 - p. 874-882 , 2020

Link: https://doi.org/10.1007/..

2

The role of FDG-PET scanning in assessing lymphoma in 2012:

Bodet-Milin, C. ; Eugène, T. ; Gastinne, T....
Diagnostic and Interventional Imaging. 94 (2013) 2 - p. 158-168 , 2013

Link: https://doi.org/10.1016/..

3

Staging and monitoring in the treatment of lymphomas:

Dupas, B. ; Augeul-Meunier, K. ; Frampas, E....
Diagnostic and Interventional Imaging. 94 (2013) 2 - p. 145-157 , 2013

Link: https://doi.org/10.1016/..

4

FDG-PET in the evaluation of myeloma in 2012:

Bodet-Milin, C. ; Eugène, T. ; Bailly, C....
Diagnostic and Interventional Imaging. 94 (2013) 2 - p. 184-189 , 2013

Link: https://doi.org/10.1016/..

5

FDG-PET in Follicular Lymphoma Management:

Bodet-Milin, C. ; Eugène, T. ; Gastinne, T....
Journal of Oncology. 2012 (2012) - p. 1-8 , 2012

Link: https://doi.org/10.1155/..

6

PET molecular imaging in oncology: interest of other radion..:

Rousseau, C. ; Bodet-Milin, C. ; Ansquer, C...
Physica Medica. 27 (2011) - p. S26 , 2011

Link: https://doi.org/10.1016/..

7

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Herve ; Obéric, Lucie...
boreal:238761. , 2021

Link: http://hdl.handle.net/20..

8

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750. , 2021

Link: https://hal.science/hal-..

9

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750. , 2021

Link: https://hal.science/hal-..

10

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, S ; Ghesquieres, H ; Obéric, L...
urn:issn:0006-4971. , 2021

Link: https://orbi.uliege.be/h..

11

Standardization of 18F-FDG-PET/CT According to Deauville Cr..:

Zamagni, E ; Nanni, C ; Dozza, L...
Zamagni , E , Nanni , C , Dozza , L , Carlier , T , Bailly , C , Tacchetti , P , Versari , A , Chauvie , S , Gallamini , A , Gamberi , B , Caillot , D , Patriarca , F , Macro , M , Boccadoro , M , Garderet , L , Barbato , S , De Fanti , S , Perrot , A , Gay , F , Sonneveld , P , Karlin , L , Cavo , M , Bodet-Milin , C , Moreau , P & Kraeber-Bodéré , F 2021 , ' Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma ' , Journal of clinical oncology : official journal of the American Society of Clinical Oncology , vol. 39 , no. 2 , pp. 116-125 . https://doi.org/10.1200/jco.20.00386. , 2021

Link: https://pure.eur.nl/en/p..

12

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750. , 2021

Link: https://hal.science/hal-..

13

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750. , 2021

Link: https://hal.science/hal-..

14

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750. , 2021

Link: https://hal.science/hal-..

15

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750. , 2021

Link: https://hal.science/hal-..